It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

- 1 Title: Association between having a pregnancy complicated by vaginal bleeding and risk of
- 2 cancer
- 3 Elena Dudukina,¹ Erzsébet Horváth-Puhó,¹ Henrik Toft Sørensen,¹ Vera Ehrenstein¹
- ¹Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus,
- 5 Denmark
- 6 Corresponding author:
- 7 Elena Dudukina
- 8 Olof Palmes Alle 43-45
- 9 8200, Aarhus N, Denmark
- 10 Email: <u>e.dudukina@clin.au.dk</u>
- 11 ORCID identifier: 0000-0002-4238-049X

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 ABSTRACT (MAX 200/200)

-	ADSTRACT (MAA 200/200)
2	Background: A full-term pregnancy is associated with a lower cancer risk. The risk of cancer in
3	women with vaginal bleeding in pregnancy is unknown.
4	Methods: We conducted a registry-based cohort study (1995-2017) in Denmark. We included
5	pregnancies (n=37 082) affected by vaginal bleeding (VB) within 20 gestational weeks among
6	35 514 women, VB-unaffected pregnancies (n=1 363 614) among 783 314 women, pregnancies
7	ending in a termination (n=324 328) among 239 638 women or miscarriage (n=137 104) among
8	121 353 women. We computed absolute risk of cancer and hazard ratios (HR) with 95%
9	confidence intervals (CI) adjusted for age, calendar year, morbidity, and socioeconomic factors
10	using Cox proportional hazards regression.
11	Results : At the end of the 24-year follow-up, there were 1 320 events among VB-affected cohort,
12	40 420 events among VB-unaffected cohort, 10 300 events among termination cohort, and 4 790
13	events among miscarriage cohort. The HR for any cancer was 1.03 (95% CI: 0.97-1.08) when
14	comparing VB-affected vs VB-unaffected pregnancies, 1.03 (95% CI: 0.97-1.09) vs terminations,
15	and 0.90 (95% CI: 0.84-0.95) vs miscarriages. Similar results were obtained for site-specific
16	cancers.
17	Conclusions: We found no strong evidence for an association between vaginal bleeding in
18	pregnancy and an increased risk of cancer.
19	Abstract word count: 200
20	Word count: 2992

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 INTRODUCTION

- 2 Gestation is sustained with progesterone, which may play a protective role for hormone-related
- 3 cancers, such as endometrial and breast cancer (1,2). Threatened miscarriage and completed
- 4 miscarriage share several biologic mechanisms, including increased levels of pro-inflammatory
- 5 cytokines (3–5) and decreased levels of progesterone (6,7). Threatened miscarriage affects up to 30%
- 6 (8–12) of clinically identified pregnancies and manifests as vaginal bleeding (VB) before 20
- 7 gestational weeks of a viable intrauterine pregnancy (8,9,13). About 30-50% (6,14,15) of VB-affected
- 8 pregnancies may progress to a completed miscarriage (16–18). Previously reported risk factors for VB
- 9 in pregnancy are advanced women's age at pregnancy (\geq 35 years), obesity, smoking, alcohol abuse,
- 10 inflammation, and low plasma levels of progesterone in gestation (16,19–26).
- 11 A full-term pregnancy is associated with a 40% reduction in risks of breast, endometrial, and ovarian
- 12 cancer (27,28). Pregnancies with a duration of 33 gestational week or more were not associated with
- 13 increased risk of breast cancer in contrast to pregnancies with shorter gestation (1,2,27). In line with
- 14 this, a full-term pregnancy is associated with a 40% cancer risk reduction (27,28); however, reduction
- 15 in cancer risk after a pregnancy ending in a miscarriage is only 10% (1). The long-term risk of cancer
- 16 in women with a pregnancy complicated by VB within 20 gestational weeks is unknown and could be
- 17 increased due to underlying inflammatory pathways and reduced level of progesterone. In this cohort
- 18 study, we investigated an association between having a VB-affected pregnancy ending in childbirth
- 19 with the subsequent risk of cancer as compared with VB-unaffected pregnancy ending in childbirth,
- 20 pregnancy ending in a termination or pregnancy ending in miscarriage.
- 21

22 METHODS

23 Setting, design and data sources

- 24 This was a registry-based cohort study conducted using individual-level linked data from Danish
- 25 health and administrative registries, set within Denmark's universal and tax-funded health care system
- 26 (29). The Civil Registration System assigns personal identifiers and contains data on date of birth,
- vital and civil status, and dates of immigration and emigration (29,30). Data on all deliveries are
- 28 captured by the Medical Birth Registry (MBR) starting in 1973 and includes women's and pregnancy-
- 29 related characteristics including but not limited to women's age at delivery, gestational age, and parity
- 30 (31,32). Smoking status in pregnancy is collected by the MBR from 1991 and body-mass index (BMI)
- from 2004. Information on stillbirths at the gestational age of at least 28 full weeks is available in the
- 32 MBR before April 2004 and at 22 full gestational weeks afterwards; livebirths are recorded regardless
- 33 of gestational age. Information on highest education level (33), employment status (34) and personal
- income (35) are stored at Statistics Denmark and available starting in 1980-1981 (36). Hospital
- encounters are recorded in the Danish National Patient Registry (DNPR) (37,38), including data on

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

- 1 medical procedures and discharge diagnoses, coded using the International Classification of Diseases,
- 2 8th revision (ICD-8) in 1977-1993 and 10th revision (ICD-10) thereafter (37). Hospital admissions are
- 3 available in the DNPR from 1977, while outpatient clinic and emergency room visits are recorded

4 from 1995 onwards (37,38). Admissions and outpatient specialist visits due to psychiatric conditions

- 5 are captured as part of the the DNPR (39) and were available for this study from 1995. The Danish
- 6 National Prescription Registry (40) captures data on prescribed medication dispensings from 1995
- 7 onwards and records the Anatomical Therapeutic Classification (ATC) codes of the dispensed drugs
- 8 and the dates when the prescriptions were redeemed. The Danish Cancer Registry (DCR) captures all

9 primary incident cancer diagnoses (with compulsory reporting from 1987) and contains data on

10 tumour morphology (41).

11 Study population

12 Using the MBR, we identified all pregnancies ending in a liveborn or stillborn delivery between 1995

and 2017. We kept one record per delivery of a multifetal pregnancy. Using the DNPR, we obtained

14 and linked data on VB within 20 gestational weeks starting from the last menstrual period date,

15 computed by subtracting gestational age at delivery from the delivery date (Table 1 in the electronic

supplementary material). Pregnancies ending in a delivery without a VB record in the DNPR within

17 20 weeks of gestation were classified as VB-unaffected. The date of delivery served as the start of the

18 follow-up for both VB-affected and VB-unaffected cohorts of pregnancies.

19 Using the DNPR, we identified pregnancies ending in a miscarriage (spontaneous abortion) or a

20 termination (medical or surgical abortion) in 1995-2017, using relevant diagnostic and procedure

21 codes (Table 1 in the electronic supplementary material). To avoid multiple counting of the same

22 miscarriages or terminations, a woman with repeated event-qualifying diagnostic or procedure code

23 was allowed to re-enter the cohort after 180 days, whereby she was assumed to have a new pregnancy.

- 24 When multiple dates associated with the pregnancy termination or miscarriage were available (date of
- 25 procedure, date of hospital admission, date of hospital discharge), we included the earliest. The date
- 26 of the hospital-based encounter for pregnany termination or miscarriage served as the index date. We
- 27 excluded from the study pregnancy records of women with cancer or HIV/AIDS diagnosis before the

index date, records with missing women's age at the pregnancy end, and pregnancies ending in

29 childbirth with missing gestational age. The flow-chart for study population construction is presented

30 in Figure 1.

31 Cancer outcomes

32 Using the DCR, we ascertained incident diagnoses of cancer. We investigated the long-term risk of

33 any cancer; cancers at specific anatomic sites, focusing on breast, cervical, ovarian and fallopian tube,

34 and uterine cancer, and cancers grouped as hormone-related, haematological, immune-related,

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 smoking or alcohol-related, obesity-related, and cancers of neurological origin, as previously

2 described (42–44)(Table 1 in the electronic supplementary material).

3 Covariables

4 The potential confounding factors were age, calendar year of pregnancy end, women's parity, number 5 of previous identifiable pregnancies, socioeconomic factors (education, employment, and year-6 specific income level divided into quartiles), reproductive factors (pre-index date vaginal bleeding, 7 termination, or miscarriages, placental complications in previous and current deliveries), chronic 8 somatic conditions (obesity, polycystic ovary syndrome, thyroid disorders, chronic kidney disease, 9 chronic liver disease, hyperlipidaemia, diabetes, hypertension, and connective tissue disorder), and 10 history of any psychiatric condition using the entire available lookback period. We additionally 11 adjusted for the use of NSAIDs and steroids for systemic use before the 12 weeks of gestation for VB-12 affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages 13 using 365 days lookback period for NSAIDs and the entire available lookback period for steroids for 14 systemic use. In the comparisons of pregnancies ending in childbirth, we additionally controlled for 15 placental complications (hypertensive disorders of pregnancy, placenta praevia, and abruptio 16 placenta) not only at the previous deliveries but also at the index pregnancy as a late manifesting 17 proxy of potential placental dysfunction early in pregnancy.

18 Statistical analyses

19 We followed each woman from the index date until the earliest of cancer diagnosis, death, emigration, 20 or end of the study on 31 December 2018. We constructed the cumulative incidence curves of any 21 cancer at the end of a 24-year follow-up while treating death and emigration as competing events 22 (Figure 1 in the electronic supplementary material) and calculated cancer incidence rates (IRs) per 23 10 000 person-years (PYs). We used Cox proportional-hazards regression to compute crude and 24 adjusted hazard ratios (HRs) for the cancer outcomes. In the analyses of all pregnancies, with each 25 subsequent pregnancy of a woman, we accounted for the reproductive history, including prior 26 exposure status, at the previous pregnancies. We computed robust 95% confidence intervals (CIs) 27 taking into account that different non-independent pregnancies of the same woman were analysed 28 (45). Further, we repeated the main analyses following women's first identifiable pregnancy. In 29 separate sets of analyses, we compared the risk of cancer outcomes following a VB-affected 30 pregnancy vs 1) VB-unaffected pregnancy, 2) termination, or 3) miscarriage. 31 The HRs were adjusted for potential confounders (women's age at pregnancy end, calendar period, 32 socioeconomic factors [education, employment, and year-specific income level divided into quartiles], 33 reproductive history [parity, number of pre-index date identifiable pregnancies, history of VB,

- 34 terminations or miscarriages, hypertensive disorders of pregnancy, placenta praevia, abruptio
- 35 placentae] and placenta-related complications at the current pregnancy ending in delivery

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

- 1 [preeclampsia-eclampsia, placenta praevia, abruptio placentae]; pre-index date thyroid conditions,
- 2 obesity, polycystic ovary syndrome, chronic obstructive pulmonary disease, chronic liver and kidney
- 3 diseases, connective tissue disorders and medication use [non-steroid anti-inflammatory drugs and
- 4 steroid for systemic use]). In analyses of all identifiable pregnancies of a woman, we ascertained the
- 5 history of all covariables before the index date in a time-varying manner updating the covariables'
- 6 status at each subsequent pregnancy.
- 7 In a sensitivity analysis, we investigated the association of VB-affected pregnancy with any cancer
- 8 and hormone-related, haematological, immune-related, smoking or alcohol-related, obesity-related,
- 9 and cancers of neurological origin additionally adjusted for women's BMI in analyses of pregnancies
- 10 ending in a delivery; however, the follow-up was short and accrued few events. We additionally
- 11 investigated the associations with cancer outcomes restricting the data to women having their last
- 12 recorded pregnancy at the age of 40 years or later as the age, when most women likely reach the
- 13 desired family size. We did not impute missing values and included variables with missing data in the
- 14 statistical models using "missing" as a category.
- 15 We used log-minus-log plots to evaluate the proportionality of hazards assumptions, and the curves
- 16 were close to parallel over the follow-up period for overall cancer. All analyses were conducted on the
- 17 servers of Statistics Denmark (36) using RStudio (46) and R software for statistical computing (47)
- 18 versions 3.6.0-4.1.0, including the following packages and their dependencies: tidyverse (48), ggplot2
- 19 (49), survival (45), cmprsk (50), prodlim (51), and epiR (52). Reported counts were masked to protect
- 20 personal data, in compliance with the Statistics Denmark regulations.
- 21 Ethics
- 22 Patient consent or ethical approval is not required for registry-based research according to Danish
- 23 legislation. This study was reported to the Danish Data Protection Agency (53) through registration at
- Aarhus University (record number: AU-2016-051-000001, sequential number 605).

25 RESULTS

26 Descriptive characteristics

- 27 There were 37 082 VB-affected pregnancies among 35 514 women; 1 363 614 VB-unaffected
- pregnancies among 783 314 women; 324 328 terminations among 239 638 women and 137 104
- 29 miscarriages among 121 353 women in 1995-2017 (Figure 1). Women's age, parity, civil status,
- 30 employment, income, obesity, chronic pulmonary, chronic liver and kidney conditions, alcohol abuse,
- 31 and medication use had similar distributions for VB-affected and VB-unaffected pregnancy cohorts.
- 32 Of women with VB-affected vs VB-unaffected pregnancies, 29.0% vs 35.0% had higher education,
- 33 13.0% vs 4.9% had a previous record of VB diagnosis irrespective of pregnancy outcome, 6.2% vs
- 34 2.1% had a history of a previous VB episode within 20 gestational weeks of a pregnancy ending in a

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

- 1 delivery, 22.0% vs 12.0% had at least one previous miscarriage; 19.0% vs 15.0% were smokers
- 2 (Table 1).
- 3 Pregnancies ending in a termination were more likely to be among women who were younger (<24
- 4 years), unmarried, nulliparous and unemployed, had a higher prevalence of psychiatric conditions
- 5 history, a lower level of the highest attained education and were in the first income quartile compared
- 6 with pregnancies ending in a delivery or miscarriage (Table 1). Pregnancies ending in a miscarriage
- 7 were more likely than VB-affected pregnancies to be of women older than 35 years and 15.0% had a
- 8 previous miscarriage (Table 1).

9 Cumulative incidences and incidence rates of the cancer outcomes

- 10 The median (25th-75th percentile) follow-up was 12.6 (6.9-18.2) years. At the end of the follow-up,
- 11 there were 1 320 cancer events following VB-affected pregnancy, 40 420 events following VB-
- 12 unaffected pregnancy, 10 300 events following a termination and 4 790 events following a
- 13 miscarriage (Table 2). At the end of the 24-year follow-up, the cumulative incidence of any cancer
- 14 was 7.4% following VB-affected pregnancy and 7.5% following VB-unaffected pregnancy, 7.3%
- 15 following termination and 7.9% following a miscarriage (Figure 1 in the electronic supplementary
- 16 material). The cumulative incidence of groups of site-specific cancers was also similar between the
- 17 investigated cohorts. Cancers classified as hormone-related were the most prevalent group with
- 18 cumulative incidences at the end of follow-up of 3.2%, 3.0%, 2.6%, and 3.0% following VB-affected
- 19 pregnancy, VB-unaffected pregnancy, termination, and miscarriage, respectively.
- 20 The incidence rate per 10 000 PYs of any cancer was 25.36 (95% CI: 24.02-26.76) for VB-affected
- 21 pregnancies and 24.04 (95% CI: (23.81-24.28) for VB-affected pregnancies (Table 2). The incidence
- rates per 10 000 PYs of hormone-related cancers were 9.83 (9.01-10.71) for VB-unaffected
- pregnancies, 9.19 (9.05-9.34) for VB-affected pregnancies, 8.20 (7.94-8.48) for terminations, and
- 24 10.56 (10.09-11.05) for miscarriages. Similarly, the incidence rates per 10 000 PYs of smoking or
- 25 alcohol-related cancers and obesity-related cancers were slightly higher following VB-affected than
- 26 VB-unaffected pregnancy. The incidence rates of premenopausal breast cancer, cervical cancer, ovary
- and fallopian tube cancer, uterine cancer, and cancers at other sites were similar for all investigated
- cohorts (Table 2 and Table 2 in the electronic supplementary material).

29 Hazard ratios for the cancer outcomes

- 30 The HR for any cancer in the VB-affected pregnancy cohort was 1.03 (95% CI: 0.97-1.08) vs VB-
- 31 unaffected pregnancy cohort, 1.03 (95% CI: 0.97-1.09) vs termination cohort, and 0.90 (95% CI:
- 32 0.84-0.95) vs miscarriage cohort. In the analyses including the first pregnancy of a woman, the
- 33 adjusted models yielded nearly identical results as analyses including all identifiable pregnancies of a
- 34 woman (Table 3).

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 There was no strong evidence for an association between VB-affected pregnancy and subsequent risk 2 of hormone-related, haematological, immune-related, obesity-related, cancers of neurologic origin, or 3 other cancers across all contrasts (Table 3). When investigating the risk of smoking or alcohol-related 4 cancers following VB-affected vs VB-unaffected pregnancy the HR was 0.98 (95% CI: 0.79-1.22). 5 However, when following a first identifiable VB-affected vs VB-unaffected pregnancy of a woman, 6 we observed 1.3-fold increased hazard of smoking or alcohol-related cancers (HR: 1.29, 95% CI: 7 0.78-2.13) (Table 3). For contrasts of VB-affected pregnancy ending in childbirth vs pregnancy 8 ending in termination or miscarriage, the HRs for smoking or alcohol-related cancers were consistent 9 with slightly reduced risk to no association (HR: 0.84, 95% CI: 0.65-1.09 and HR: 0.77, 95% CI: 10 0.57-1.04, respectively) in analyses of all identifiable pregnancies. The latter associations could not be 11 adjusted for women's smoking status, since this information was only available for pregnancies 12 ending in a delivery. 13 As compared with having VB-unaffected pregnancy, there was no evidence of an increased risk of 14 premenopausal breast cancer (HR: 1.01, 95% CI: 0.92-1.11), cervical cancer (0.95, 0.78-1.16), ovary 15 and fallopian tube cancer (1.20, 0.84-1.71), and uterine cancer (0.85, 0.49-1.42) following VB-16 affected pregnancy (Table 4). Similarly, we found no association with other investigated site-specific 17 cancers across comparisons with VB-unaffected pregnancy cohort and cohorts of pregnancies ending 18 in a termination or miscarriage (Table 3 in the electronic supplementary material). 19 Sensitivity analysis of pregnancies ending in delivery from 2004 onwards with additional adjustment 20 for woman's BMI in pregnancy showed results generally consistent with the findings from the main 21 analyses. The HR for smoking or alcohol-related cancers following a first identifiable VB-affected vs 22 VB-unaffected pregnancy of a woman shifted below the null value (HR: 0.50, 95% CI: 0.19-1.33); 23 however, the estimate should be interpreted with caution since it was based on few cancer events and, 24 thus, was imprecise (Table 4 in the electronic supplementary material). HRs for other cancers at 25 specific sites are available in Table 5 in the electronic supplementary material. There was no 26 increased risk of any cancer in analyses of women having their last identifiable pregnancy at the age 27 of 40 years or later (Table 6 in the electronic supplementary material). 28 DISCUSSION

29 **Principal findings**

- 30 In this registry-based cohort study, we found no evidence of an association between VB in pregnancy
- 31 carried to delivery and subsequent risk of cancer. When compared with having VB-unaffected
- 32 pregnancy, there was no increased risk of any cancer and specifically breast, cervical, ovary and
- fallopian tube, and uterine cancer in women having VB-affected pregnancy. Analysis of a first
- 34 identifiable VB-affected vs VB-unaffected pregnancy of a woman showed a 1.3-fold increased hazard
- of smoking or alcohol-related cancers; however, this association attenuated towards the null value in a

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

- 1 sensitivity analysis. Similarly, we found no evidence of an association with any cancer or site-specific
- 2 cancers in women when contrasting having VB-affected pregnancy with termination or miscarriage.

3 Comparison with other studies

- 4 This study is in line with a previous Danish study reporting no association between VB in pregnancy
- 5 irrespective of pregnancy end and occult cancer (54). The results of this study also indirectly support
- 6 the findings of previous research showing that the risk of breast, ovarian and endometrial cancer was
- 7 not increased in women with a gestation duration of at least 33 weeks (1,2,27).

8 Strengths and limitations

9 Due to nearly complete administrative follow-up for every woman, selection bias at the inclusion of 10 pregnancies in the study is negligible, but potential selection bias from unidentified early miscarriages 11 cannot be ruled out. In the analyses, we controlled for multiple potential confounding factors. Data on 12 proxies of the lifestyle such as smoking and BMI were available only for pregnancies ending in 13 childbirth; moreover, data on BMI was only available for a data subset starting from 2004 and data on 14 in-vitro fertilization or subfertility status were unavailable. The 1.3-fold increased hazard of smoking 15 or alcohol-related cancers in the contrast of a first identifiable VB-affected vs VB-unaffected 16 pregnancy of a woman can potentially be explained by residual confounding by lifestyle factors such 17 as diet, physical activity, and BMI. At the same time, no lifestyle factor of women with VB in 18 pregnancy is likely to dilute the associations and, thus, is unlikely to explain the null associations in 19 analyses contrasting VB-affected pregnancy ending in delivery with having a termination or 20 miscarriage. 21 Records of VB diagnosis in pregnancy due to threatened miscarriage were not validated in the DNPR. 22 The validity of recording miscarriage diagnoses and procedures for pregnancy termination in the 23 DNPR is high (positive predictive value >90%) (37,55). We could potentially miss recurrent 24 miscarriages within 180 days of each other. However, owing to high specificity of miscarriage 25 diagnoses and few false positives, the misclassification of miscarriages is not a major concern. A 26 diagnostic work-up for threatened miscarriage includes an ultrasound for establishing pregnancy 27 viability, foetal heartbeat, and to eliminate other causes of VB such as ectopic pregnancy (8,56). The 28 prevalence of VB in this study is low (<3%) compared with estimates reported elsewhere (up to 30%) 29 (8–12). We argue that identified VB-affected pregnancies in this study had high specificity, however, 30 a sizeable proportion of VB episodes not resulting in a hospital-based encounter were missed. This 31 may cause bias only if captured episodes of VB systematically differ from all such episodes.

- 32 Owing to compulsory reporting of incident primary tumours, the accuracy of cancer diagnoses in the
- 33 DCR and its coverage is very high, with nearly 90% of tumours having a morphological verification
- 34 (41). Thus, misclassification of the outcome is unlikely in this study and is not expected to explain the
- null findings. We did not censor women who would no longer be at risk of endometrial, cervical, and

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

- 1 uterine cancers due to hysterectomy (57,58) and the risks of these cancer outcomes may be
- 2 overestimated.

3 CONCLUSION

- 4 We found no strong evidence of an association between VB in pregnancy and subsequent risk of
- 5 cancer during up to 24 years of follow-up.

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 Statements & Declarations

- 2 **Funding information:** The author(s) received no specific funding for this work. Department of
- 3 Clinical Epidemiology, Aarhus University partaking in studies with institutional funding from
- 4 regulators and pharmaceutical companies, given as research grants to and administered by Aarhus
- 5 University. None of these projects is related to the current study.
- 6 Author contributions: ED, EHP, HTS, and VE designed the study. HTS facilitated the data
- 7 application. ED prepared the statistical analysis plan and conducted statistical analyses. EHP provided
- 8 expertise and supervision of the statistical analyses. All authors participated in the discussion of the
- 9 results and their interpretation. ED drafted the manuscript, organised the writing, and produced a
- 10 graphical presentation of the results. HTS provided clinical expertise. All authors equally participated
- 11 in the critical revision of the manuscript and approved its final version. HTS is the guarantor.
- 12 Ethics approval and consent to participate: No patient consent or ethical approval is required for
- 13 registry-based research according to Danish legislation. This study was reported to the Danish Data
- 14 Protection Agency through registration at Aarhus University (record number: AU-2016-051-000001,
- 15 sequential number 605).
- 16 **Consent for publication:** Not applicable.
- 17 Data availability: The pseudonymised data used in this study are stored on and accessed via the
- 18 secure governmental servers of Denmark Statistics (https://www.dst.dk/). According to Danish
- 19 legislation, Danish research environments may be granted access to data at an individual level. For
- 20 legal reasons and to protect individuals, whose data were analysed, the dataset used in this study will
- 21 not be made public.
- 22 Competing Interests: None declared.

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 References:

- Husby A, Wohlfahrt J, Melbye M. Pregnancy duration and endometrial cancer risk: nationwide
 cohort study. BMJ. 2019 Aug 14;366:14693.
- Husby A, Wohlfahrt J, Øyen N, Melbye M. Pregnancy duration and breast cancer risk. Nat
 Commun. 2018 Oct 23;9(1):4255.
- Alijotas-Reig J, Llurba E, Gris JM. Potentiating maternal immune tolerance in pregnancy: a new challenging role for regulatory T cells. Placenta. 2014 Apr;35(4):241–8.
- Calleja-Agius J, Schembri-Wismayer P, Calleja N, Brincat M, Spiteri D. Obstetric outcome and cytokine levels in threatened miscarriage. Gynecol Endocrinol. 2011 Feb;27(2):121–7.
- Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Llurba E, Gris JM. Tumor Necrosis
 Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.
 Clin Rev Allergy Immunol. 2017 Aug;53(1):40–53.
- Coomarasamy A, Gallos ID, Papadopoulou A, Dhillon-Smith RK, Al-Memar M, Brewin J, et al.
 Sporadic miscarriage: evidence to provide effective care. The Lancet. 2021 May
 1;397(10285):1668–74.
- Lek SM, Ku CW, Allen JC, Malhotra R, Tan NS, Ostbye T, et al. Validation of serum progesterone <35nmol/L as a predictor of miscarriage among women with threatened miscarriage. BMC Pregnancy Childbirth. 2017 Mar 6;17(1):78.
- Axelsen SM, Henriksen TB, Hedegaard M, Secher NJ. Characteristics of vaginal bleeding
 during pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology.
 1995 Dec 1;63(2):131–4.
- Smits LJM, North RA, Kenny LC, Myers J, Dekker GA, Mccowan LME. Patterns of vaginal
 bleeding during the first 20 weeks of pregnancy and risk of pre-eclampsia in nulliparous
 women: results from the SCOPE study. Acta Obstetricia et Gynecologica Scandinavica.
 2012;91(11):1331–8.
- Strobino B, Pantel-Silverman J. Gestational vaginal bleeding and pregnancy outcome. American
 Journal of Epidemiology. 1989 Apr 1;129(4):806–15.
- Wijesiriwardana A, Bhattacharya S, Shetty A, Smith N, Bhattacharya S. Obstetric Outcome in
 Women With Threatened Miscarriage in the First Trimester. Obstetrics & Gynecology. 2006
 Mar;107(3):557–62.
- Saraswat L, Bhattacharya S, Maheshwari A, Bhattacharya S. Maternal and perinatal outcome in
 women with threatened miscarriage in the first trimester: a systematic review. BJOG. 2010
 Feb;117(3):245–57.
- DeVilbiss EA, Naimi AI, Mumford SL, Perkins NJ, Sjaarda LA, Zolton JR, et al. Vaginal
 bleeding and nausea in early pregnancy as predictors of clinical pregnancy loss. American
 Journal of Obstetrics and Gynecology. 2020 Oct 1;223(4):570.e1-570.e14.
- Sapra KJ, Joseph KS, Galea S, Bates LM, Louis GMB, Ananth CV. Signs and Symptoms of
 Early Pregnancy Loss. Reprod Sci. 2017 Apr;24(4):502–13.

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 2	15.	Mouri M, Hall H, Rupp TJ. Threatened Abortion [Internet]. 2017 [cited 2021 Apr 6]. Available from: http://europepmc.org/article/NBK/NBK430747
3 4 5	16.	Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, et al. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. New England Journal of Medicine. 2019 May 9;380(19):1815–24.
6 7 8 9	17.	Ogwulu CO, Goranitis I, Devall AJ, Cheed V, Gallos ID, Middleton LJ, et al. The cost- effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding: an economic evaluation based on the PRISM trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2020;127(6):757–67.
10 11 12	18.	Quenby S, Gallos ID, Dhillon-Smith RK, Podesek M, Stephenson MD, Fisher J, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. The Lancet. 2021 May 1;397(10285):1658–67.
13 14 15	19.	Sipilä P, Hartikainen Sorri AL, Oja H, Wendt LV. Perinatal outcome of pregnancies complicated by vaginal bleeding. BJOG: An International Journal of Obstetrics & Gynaecology. 1992;99(12):959–63.
16 17	20.	Lashen H, Fear K, Sturdee DW. Obesity is associated with increased risk of first trimester and recurrent miscarriage: matched case-control study. Hum Reprod. 2004 Jul;19(7):1644–6.
18 19 20 21	21.	Ong CYT, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG: An International Journal of Obstetrics & Gynaecology. 2000;107(10):1265–70.
22 23 24 25	22.	Ku CW, Allen JC, Lek SM, Chia ML, Tan NS, Tan TC. Serum progesterone distribution in normal pregnancies compared to pregnancies complicated by threatened miscarriage from 5 to 13 weeks gestation: a prospective cohort study. BMC Pregnancy Childbirth. 2018 Sep 5;18(1):360.
26 27 28	23.	Maconochie N, Doyle P, Prior S, Simmons R. Risk factors for first trimester miscarriage— results from a UK-population-based case–control study. BJOG: An International Journal of Obstetrics & Gynaecology. 2007;114(2):170–86.
29 30 31	24.	Coomarasamy A, Harb HM, Devall AJ, Cheed V, Roberts TE, Goranitis I, et al. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. Health Technol Assess. 2020 Jun;24(33):1–70.
32 33	25.	Arck PC, Rose M, Hertwig K, Hagen E, Hildebrandt M, Klapp BF. Stress and immune mediators in miscarriage. Human Reproduction. 2001 Jul 1;16(7):1505–11.
34 35	26.	Bruckner TA, Mortensen LH, Catalano RA. Spontaneous Pregnancy Loss in Denmark Following Economic Downturns. Am J Epidemiol. 2016 Apr 15;183(8):701–8.
36 37 38 39	27.	Jordan SJ, Na R, Weiderpass E, Adami HO, Anderson KE, Brandt PA van den, et al. Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. International Journal of Cancer. 2021;148(9):2068–78.

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 2 3	28.	Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast cancer research□: BCR. 2006;8(4):R43.
4 5	29.	Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014 Aug;29(8):541–9.
6 7	30.	Pedersen CB. The Danish Civil Registration System. Scandinavian Journal of Public Health. 2011;39(7_suppl):22–5.
8 9	31.	Knudsen LB, Olsen J. The Danish Medical Birth Registry. Danish medical bulletin. 1998 Jun;45(3):320–3.
10 11	32.	Bliddal M, Broe A, Pottegard A, Olsen J, Langhoff-Roos J. The Danish Medical Birth Register. Eur J Epidemiol. 2018 Jan;33(1):27–36.
12 13	33.	Jensen VM, Rasmussen AW. Danish Education Registers. Scand J Public Health. 2011 Jul;39(7 Suppl):91–4.
14 15	34.	Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. Scand J Public Health. 2011 Jul 1;39(7_suppl):95–8.
16 17	35.	Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011 Jul;39(7 Suppl):103–5.
18	36.	Statistics Denmark [Internet]. 2021 [cited 2021 Jun 30]. Available from: https://www.dst.dk/en
19 20 21	37.	Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90.
22 23 24	38.	Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, et al. Nordic Health Registry-Based Research: A Review of Health Care Systems and Key Registries. CLEP. 2021 Jul 19;13:533–54.
25 26	39.	Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public Health. 2011 Jul;39(7 Suppl):54–7.
27 28 29	40.	Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data Resource Profile: The Danish National Prescription Registry. Int J Epidemiol. 2017 Jun 1;46(3):798–798f.
30	41.	Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011 Jul;39(7 Suppl):42–5.
31 32	42.	Ording AG, Veres K, Farkas DK, Adelborg K, Sorensen HT. Risk of cancer in patients with epistaxis and haemoptysis. Br J Cancer. 2018 Mar 20;118(6):913–9.
33 34 35	43.	Gribsholt SB, Cronin-Fenton D, Veres K, Thomsen RW, Ording AG, Richelsen B, et al. Hospital-diagnosed overweight and obesity related to cancer risk: a 40-year Danish cohort study. Journal of Internal Medicine. 2020;287(4):435–47.

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 2 3	44.	Elser H, Skajaa N, Ehrenstein V, Fuglsang CH, Farkas DK, Sørensen HT. Cancer risk in patients with migraine: A population-based cohort study in Denmark. Headache: The Journal of Head and Face Pain. 2022;62(1):57–64.
4 5	45.	Therneau TM, Thomas L, Elizabeth A, Cynthia C. survival: Survival Analysis [Internet]. 2021 [cited 2021 Apr 6]. Available from: https://CRAN.R-project.org/package=survival
6 7	46.	RStudio Team. RStudio: Integrated Development for R [Internet]. Boston, MA: RStudio, PBC; 2020. Available from: http://www.rstudio.com/
8 9	47.	R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria; 2013. Available from: http://www.R-project.org/
10 11	48.	Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to the Tidyverse. Journal of Open Source Software. 2019 Nov 21;4(43):1686.
12 13	49.	Wickham H. ggplot2: Elegant Graphics for Data Analysis:Elegant Graphics for Data Analysis [Internet]. Springer-Verlag New York; 2016. Available from: https://ggplot2.tidyverse.org
14 15	50.	Gray B. cmprsk: Subdistribution Analysis of Competing Risks [Internet]. 2020 [cited 2021 Mar 31]. Available from: https://CRAN.R-project.org/package=cmprsk
16 17	51.	Gerds TA. prodlim: Product-Limit Estimation for Censored Event History Analysis [Internet]. 2019 [cited 2021 Mar 31]. Available from: https://CRAN.R-project.org/package=prodlim
18 19 20	52.	Nunes MS and ES with contributions from T, Heuer C, Marshall J, Sanchez J, Thornton R, Reiczigel J, et al. epiR: Tools for the Analysis of Epidemiological Data [Internet]. 2021 [cited 2021 Jul 29]. Available from: https://CRAN.R-project.org/package=epiR
21 22 23	53.	Datatilsynet. Datatilsynet/The Danish Data Protection Agency [Internet]. Datatilsynet/The Danish Data Protection Agency. [cited 2020 Sep 16]. Available from: http://www.datatilsynet.dk/english
24 25 26	54.	Dudukina E, Farkas DK, Horváth Puhó E, Prandoni P, Sørensen HT, Ehrenstein V. Vaginal bleeding in early pregnancy and risk of occult cancer. International Journal of Gynecology & Obstetrics. 2019;146(3):387–9.
27 28 29	55.	Lohse SR, Farkas DK, Lohse N, Skouby SO, Nielsen FE, Lash TL, et al. Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients. Clin Epidemiol. 2010 Oct 27;2:247–50.
30 31 32 33	56.	Norwitz ER, Park JS, Lockwood CJ, Barss V. Overview of the etiology and evaluation of vaginal bleeding in pregnancy - UpToDate [Internet]. 2021 [cited 2021 Aug 30]. Available from: https://www.uptodate.com/contents/overview-of-the-etiology-and-evaluation-of-vaginal-bleeding-in-pregnancy
34 35 36	57.	Gustafson LW, Booth BB, Kahlert J, Ørtoft G, Mejlgaard E, Clarke MA, et al. Trends in hysterectomy-corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise? International Journal of Cancer. 2021;148(3):584–92.

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

- 1 58. Lycke KD, Kahlert J, Damgaard R, Mogensen O, Hammer A. Trends in Hysterectomy
- 2 Incidence Rates During 2000-2015 in Denmark: Shifting from Abdominal to Minimally
- 3 Invasive Surgical Procedures. CLEP. 2021 Jun 1;13:407–16.

4

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

Figure 1. Flow chart for the study population ascertainment

Standalone figure

Table 1. Descriptive characteristics of the VB-affected pregnancy and comparator cohorts, Denmark, 1995-2017

	Exposed cohort	Comparator cohorts		
	VB-affected	VB-unaffected	-	
	pregnancy,	pregnancy,	Termination,	Miscarriage,
	$N = 37\ 082$	N = 1 363 614	N = 324 328	N = 137 104
Women, N	35 514	783 314	239 638	121 353
Characteristic	$n(\%)^{a}$	n (%) ^a	$n(\%)^{a}$	$n (\%)^{a}$
Age at pregnancy end, years				
<20	565 (1.5)	20 010 (1.5)	46 215 (14.0)	4 635 (3.4)
20-24	5 030 (14.0)	163 880 (12.0)	74 390 (23.0)	17 410 (13.0)
25-29	12 265 (33.0)	464 200 (34.0)	68 090 (21.0)	37 455 (27.0)
30-34	12 380 (33.0)	476 500 (35.0)	65 425 (20.0)	39 820 (29.0)
35-39	5 720 (15.0)	202 705 (15.0)	49 490 (15.0)	26 205 (19.0)
40+	1 125 (3.0)	36 320 (2.7)	20 725 (6.4)	11 575 (8.4)
Calendar year of pregnancy en	d			
1995-1999	12 660 (34.0)	308 315 (23.0)	88 940 (27.0)	33 565 (24.0)
2000-2004	8 265 (22.0)	243 075 (18.0)	63 420 (20.0)	25 470 (19.0)
2005-2008	7 220 (19.0)	304 450 (22.0)	72 305 (22.0)	33 885 (25.0)
2009-2013	4 730 (13.0)	229 010 (17.0)	50 600 (16.0)	25 365 (19.0)
2013-2017	4 205 (11.0)	278 765 (20.0)	49 070 (15.0)	18 820 (14.0)
Smoking in pregnancy				
Smoker	6 990 (19.0)	209 855 (15.0)	NT	
Non-smoker	26 205 (71.0)	1 049 620 (77.0)	Not available	
Missing	6 990 (19.0)	209 855 (15.0)		
Parity at the index date ^b				
Nulliparous	0 (0.0)	0 (0.0)	205 310 (63.0)	110 460 (81.0)
Primiparous	17 105 (46.0)	629 085 (46.0)	32 775 (10.0)	10 890 (7.9)
Multiparous	19 980 (54.0)	734 530 (54.0)	86 245 (27.0)	15 750 (11.0)
Pregnancy number at the index	date			
1	11 300 (30.0)	512 700 (38.0)	112 340 (35.0)	43 995 (32.0)
2	11 545 (31.0)	447 730 (33.0)	59 810 (18.0)	39 945 (29.0)
3	7 045 (19.0)	232 420 (17.0)	58 840 (18.0)	25 525 (19.0)
3+	7 190 (19.0)	170 765 (13.0)	93 340 (29.0)	27 640 (20.0)
Civil status				
Married or in partnership	22 330 (60.0)	833 375 (61.0)	102 500 (32.0)	68 615 (50.0)
Not married	10 530 (28.0)	387 465 (28.0)	165 230 (51.0)	43 105 (31.0)
Missing	4 225 (11.0)	142 775 (10.0)	56 600 (17.0)	25 385 (19.0)
Employment status				
Employed	26 970 (73.0)	1 017 935 (75.0)	194 860 (60.0)	98 695 (72.0)
Retirement or state pension	3 395 (9.2)	100 590 (7.4)	41 220 (13.0)	13 030 (9.5)
Unemployed	5 750 (16.0)	201 410 (15.0)	80 905 (25.0)	21 330 (16.0)
Missing	965 (2.6)	43 680 (3.2)	7 340 (2.3)	4 055 (3.0)
Highest achieved education				
Basic education	9 815 (26.0)	272 030 (20.0)	145 845 (45.0)	35 680 (26.0)
High school or similar	15 095 (41.0)	553 485 (41.0)	109 340 (34.0)	53 405 (39.0)
Higher education (bachelor's	× /	× /		· /
degree, bachelor's degree	10 605 (29.0)	473 525 (35.0)	48 940 (15.0)	41 135 (30.0)
equivalent or higher)	× /	× /	× /	· /
Missing	1 570 (4.2)	64 575 (4.7)	20 205 (6.2)	6 885 (5.0)
Year-specific income, quartiles		. ,	× /	. /
Q1	8 895 (24.0)	282 190 (21.0)	130 535 (40.0)	33 130 (24.0)
Q2	9 460 (26.0)	326 595 (24.0)	82 285 (25.0)	34 490 (25.0)
Q3	8 870 (24.0)	359 000 (26.0)	52 580 (16.0)	32 695 (24.0)

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

	Exposed cohort	rt Comparator cohorts		
	VB-affected	VB-unaffected		
	pregnancy,	pregnancy,	Termination,	Miscarriage,
	$N = 37\ 082$	N = 1 363 614	N = 324 328	N = 137 104
Women, N	35 514	783 314	239 638	121 353
Characteristic	n (%) ^a	n (%) ^a	$n(\%)^{a}$	n (%) ^a
Q4	9 185 (25.0)	362 210 (27.0)	47 165 (15.0)	33 220 (24.0)
Missing	670 (1.8)	33 620 (2.5)	11 760 (3.6)	3 565 (2.6)
Origin				
Danish	30 930 (83.0)	1 158 025 (85.0)	273 430 (84.0)	114 750 (84.0)
Non-Danish	6 145 (17.0)	205 150 (15.0)	50 900 (16.0)	22 355 (16.0)
Missing	5 (<0.1)	445 (<0.1)	-	-
Reproductive factors history				
At least one VB diagnosis	4 870 (13.0)	66 355 (4.9)	23 940 (7.4)	17 005 (12.0)
At least one VB diagnosis		20.005 (2.1)		5 0 40 (2 5)
within 20 gestational weeks of a	2 320 (6.3)	29 305 (2.1)	12 000 (3.7)	5 040 (3.7)
pregnancy ending in a delivery	0 (10 (22 0)	224 450 (16 0)	110 400 (24.0)	20,105 (22,0)
At least one termination	8 610 (23.0)	224 450 (16.0)	110 480 (34.0)	30 195 (22.0)
At least one miscarriage	8 120 (22.0)	165 775 (12.0)	38 645 (12.0)	20 940 (15.0)
Hypertensive disorders of	1 345 (3.6)	45 100 (3.3)	10 920 (3.4)	5 525 (4.0)
pregnancy Discussion	05 (0.2)	2 490 (0 2)	1.040 (0.2)	475 (0.2)
Alexantia praevia	95 (0.5) 255 (0.7)	5 480 (0.5) 5 005 (0.4)	1040(0.3)	4/5 (0.3)
Abruptio placentae	255 (0.7)	5 995 (0.4)	2 090 (0.6)	930 (0.7)
Gestational diabetes	280 (0.8)	11 020 (0.8)	2 570 (0.8)	1 550 (1.1)
Hypertensive disorders of	t pregnancy			
programan	1 610 (4.3)	51 415 (3.8)	Not available	
Eclampsia superimposed on				
preexisting hypertension	10 (<0.1)	305 (<0.1)	Not available	
Felamosia	20 (<0.1)	610 (<0.1)	Not available	
Preeclampsia	1 110 (3 0)	34730(25)	Not available	
Gestational hypertension	485 (1 3)	18490(14)	Not available	
Gestational proteinuria	320 (0.9)	8 345 (0 6)	Not available	
Placenta praevia	475 (1 3)	7 445 (0 5)	Not available	
Abruptio placentae	385 (1.0)	7 110 (0.5)	Not available	
Gestational diabetes	790 (2.1)	25 375 (1.9)	Not available	
Gestation age of a new-born.	.,, . ()	()		
weeks (median, 25 th -75 th	39.0 (38.0, 40.0)	40.0 (39.0, 41.0)	Not available	
percentile)				
Comorbidities				
Obesity diagnosis	2 480 (6.7)	103 560 (7.6)	11 355 (3.5)	6 135 (4.5)
PCOS	405 (1.1)	12 215 (0.9)	1 150 (0.4)	1 185 (0.9)
Thyroid disorders	915 (2.5)	30 135 (2.2)	5 065 (1.6)	2 945 (2.1)
COPD	450 (1.2)	14 140 (1.0)	3 415 (1.1)	1 450 (1.1)
Chronic kidney diseases	115 (0.3)	2 755 (0.2)	770 (0.2)	305 (0.2)
Chronic liver diseases	100 (0.3)	3 330 (0.2)	950 (0.3)	385 (0.3)
Hyperlipidemia	120 (0.3)	4 085 (0.3)	1 045 (0.3)	580 (0.4)
Diabetes types 1 and 2	760 (2.0)	26 795 (2.0)	3 390 (1.0)	2 775 (2.0)
Hypertension	235 (0.6)	7 575 (0.6)	1 600 (0.5)	915 (0.7)
Any connective tissue disorder	2 930 (7.9)	71 165 (5.2)	18 715 (5.8)	8 410 (6.1)
Any psychiatric condition				
identified using diagnostic	5 145 (14.0)	140 635 (10.0)	61 995 (19.0)	17 730 (13.0)
codes				
Any psychiatric condition				
identified using diagnostic	7 595 (20.0)	225 080 (17.0)	87 280 (27.0)	28 275 (21.0)
codes and psychotropic	/	(- / • •)		(*)
medication proxy				
Medication use history	2 125 (0 5)	07 400 (5 1)	10 (15 (15 0)	01 (70 (1 ())
NSAIDS ⁻	5 155 (8.5)	8/400(6.4)	49 615 (15.0)	21 6 / 0 (16.0)
Steroids for systemic use"	2 843 (7.7)	102 390 (7.5)	20 /80 (6.4)	11 380 (8.3)

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

	Exposed cohort	Exposed cohort		rts
	VB-affected	VB-unaffected		
	pregnancy,	pregnancy,	Termination,	Miscarriage,
	$N = 37\ 082$	N = 1 363 614	N = 324 328	N = 137 104
Women, N	35 514	783 314	239 638	121 353
Characteristic	$n(\%)^{a}$	$n(\%)^{a}$	$n(\%)^{a}$	$n(\%)^{a}$

^a All counts are rounded to the nearest 5 to adhere to Denmark Statistics data confidentiality requirements; percentages ≥10% are rounded to the nearest whole number and percentages <10% are rounded to the first decimal place ^b Parity was included in the statistical models as nulli- or primiparous vs multiparous

^c At least one prescription 365 days before 12 gestational weeks for VB-affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages

^d At least one prescription any time before 12 gestational weeks for VB-affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages

COPD, chronic obstructive pulmonary disease; NSAIDs, non-steroid anti-inflammatory disease; PCOS, polycistic ovary syndrome

	Exposed cohort		Comparat	or cohorts				
	VB-affected pregnancy		VB-u	naffected pregnancy	Termination			Miscarriage
	No. of events ^a	Incidence Rate, 10 000 PYs (95% CI)	No. of events ^a	Incidence Rate, 10 000 PYs (95% CI)	No. of events ^a	Incidence Rate, 10 000 PYs (95% CI)	No. of events ^a	Incidence Rate, 10 000 PYs (95% CI)
Any cancer								
All identifiable pregnancies	1 320	25.36 (24.02-26.76)	40 420	24.04 (23.81-24.28)	10 300	23.89 (23.43-24.35)	4 790	26.85 (26.10-27.62)
First pregnancy	345	23.44 (21.07-26.01	12 560	20.88 (20.51-21.24)	2 210	15.48 (14.84-16.13)	1 080	20.95 (19.73-22.23)
Hormone-related can	cers							
All identifiable pregnancies	510	9.83 (9.01-10.71)	15 455	9.19 (9.05-9.34)	3 535	8.20 (7.94-8.48)	1 885	10.56 (10.09-11.05)
First pregnancy	130	8.85 (7.43-10.47)	4 580	7.61 (7.40-7.84)	670	4.70 (4.36-5.07)	415	8.02 (7.28-8.83)
Haematological cance	ers							
All identifiable pregnancies	50	0.99 (0.74-1.29)	1 675	1.00 (0.96-1.05)	455	1.06 (0.97-1.16)	235	1.31 (1.15-1.49)
First pregnancy	15	1.08 (0.64-1.71)	645	1.07 (0.99-1.16)	125	0.87 (0.73-1.03)	55	1.03 (0.78-1.33)
Immune-related canc	ers							
All identifiable pregnancies	360	6.95 (6.26-7.69)	11,660	6.94 (6.81-7.06)	2,915	6.76 (6.52-7.01)	1 175	6.60 (6.23-6.99)
First pregnancy	105	7.23 (5.95-8.70)	4 010	6.67 (6.46-6.88)	805	5.64 (5.26-6.04)	295	5.70 (5.07-6.38)
Smoking or alcohol-r	elated cance	rs						
All identifiable pregnancies	65	1.29 (1.01-1.63)	1 885	1.12 (1.07-1.17)	770	1.79 (1.66-1.92)	300	1.69 (1.51-1.89)
First pregnancy	15	1.08 (0.64-1.71)	435	0.72 (0.66-0.79)	95	0.68 (0.55-0.83)	50	0.97 (0.73-1.27)
Obesity-related cance	ers							
All identifiable pregnancies	160	3.04 (2.59-3.54)	4 855	2.89 (2.81-2.97)	1 315	3.05 (2.89-3.22)	615	3.46 (3.20-3.74)
First pregnancy	40	2.77 (2.02-3.72)	1 410	2.34 (2.22-2.47)	220	1.56 (1.36-1.77)	135	2.58 (2.17-3.04)
Cancers of neurologic	cal origin							
All identifiable pregnancies	130	2.46 (2.06-2.92)	3 615	2.15 (2.08-2.22)	930	2.16 (2.03-2.30)	435	2.44 (2.22-2.68)

Table 2. Incidence rates of cancer following vaginal bleeding-affected pregnancy and comparator cohorts, 1995-2018

	Exposed cohort		Comparator cohorts					
	VB-	affected pregnancy	VB-ur	naffected pregnancy		Termination		Miscarriage
First pregnancy	30	1.96 (1.34-2.77)	1 165	1.94 (1.83-2.05)	235	1.65 (1.45-1.87)	110	2.17 (1.80-2.60)
Other cancers								
All identifiable pregnancies	30	0.58 (0.40-0.81)	930	0.55 (0.52-0.59)	250	0.58 (0.51-0.65)	115	0.63 (0.52-0.76)
First pregnancy	5	0.47 (0.21-0.93)	310	0.52 (0.46-0.58)	55	0.39 (0.29-0.50)	25	0.48 (0.32-0.70)
Selected site-specific of	cancers ^b							
Breast cancer, premenopausal	480	9.21 (8.41-10.06)	14 655	8.72 (8.58-8.87)	3 315	7.69 (7.44-7.96)	1 770	9.93 (9.48-10.40)
Cervical cancer	100	1.96 (1.61-2.37)	3 455	2.06 (1.99-2.13)	955	2.21 (2.08-2.36)	320	1.79 (1.60-2.00)
Ovary and fallopian tube cancer	30	0.62 (0.43-0.86)	770	0.46 (0.43-0.49)	220	0.51 (0.44-0.58)	110	0.62 (0.51-0.74)
Uterine cancer	15	0.27 (0.15-0.44)	500	0.30 (0.27-0.32)	110	0.26 (0.22-0.31)	65	0.37 (0.29-0.47)

^a All counts are rounded to the nearest 5 to adhere to Statistics Denmark data confidentiality requirements

^bComputed using all identifiable pregnancies of a woman

It is made available under a CC-BY-NC-ND 4.0 International license

It is made available under a CC-BY-NC-ND 4.0 International license . Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

Table 3. Hazard ratios for any cancer and cancer groups contrasting VB-affected pregnancy with comparator cohorts (VB-unaffected pregnancy, pregnancies ending in termination or miscarriage), Denmark, 1995-2018

		VB-affected vs	VB-affected	VB-affected
		VB-unaffected	pregnancy vs	pregnancy vs
		pregnancy ^a	termination ^b	miscarriage [⊳]
Outcome	Observations		HR (95% CI)	
Any concor	All identifiable pregnancies	1.03 (0.97-1.08)	1.03 (0.97-1.09)	0.90 (0.84-0.95)
Any cancer	First pregnancy	1.06 (0.95-1.18)	1.03 (0.91-1.17)	1.11 (0.98-1.25)
Hormone-	All identifiable pregnancies	1.02 (0.94-1.12)	1.01 (0.91-1.12)	0.98 (0.87-1.10)
related cancers	First pregnancy	1.06 (0.89-1.26)	1.08 (0.88-1.33)	1.08 (0.88-1.33)
Haematological	All identifiable pregnancies	0.95 (0.74-1.23)	0.91 (0.69-1.20)	0.85 (0.61-1.17)
cancers	First pregnancy	0.96 (0.58-1.57)	0.83 (0.47-1.47)	1.08 (0.60-1.91)
Immune-related	All identifiable pregnancies	1.02 (0.92-1.14)	0.90 (0.80-1.02)	1.06 (0.92-1.22)
cancers	First identifiable	1.06 (0.87-1.28)	0.97 (0.78-1.21)	1.22 (0.97-1.54)
Smoking or	All identifiable pregnancies	0.98 (0.76-1.25)	0.84 (0.65-1.09)	0.77 (0.57-1.04)
alcohol-related cancers	First identifiable	1.29 (0.78-2.13)	1.19 (0.67-2.10)	1.25 (0.70-2.24)
Obesity-related	All identifiable pregnancies	1.01 (0.86-1.18)	0.99 (0.83-1.18)	0.88 (0.72-1.08)
cancers	First identifiable	1.11 (0.81-1.51)	1.10 (0.76-1.60)	1.07 (0.74-1.54)
Cancers of	All identifiable pregnancies	1.14 (0.96-1.36)	1.21 (0.99-1.48)	1.00 (0.79-1.27)
neurological origin	First identifiable	1.00 (0.69-1.45)	1.04 (0.68-1.59)	0.89 (0.58-1.35)
Other concore	All identifiable pregnancies	1.00 (0.70-1.44)	0.97 (0.64-1.47)	0.99 (0.61-1.61)
	First identifiable	0.90 (0.42-1.90)	1.62 (0.68-3.85)	1.15 (0.48-2.74)

^a Adjusted for age, calendar year of pregnancy end, women's parity and number of previous identifiable pregnancies, socioeconomic factors (education, employment, and year-specific income level divided into quartiles based on all included pregnancies), smoking in pregnancy, reproductive history (pre-index date vaginal bleeding, termination, or miscarriages, placental complication in previous and current deliveries), history of chronic somatic conditions, any psychiatric condition, and use of NSAIDs and steroids for systemic use before the 12 weeks of gestation for VB-affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages

^bAnalyses could not be adjusted for smoking in pregnancy since the data were unavailable for pregnancies ending in a termination or miscarriage

It is made available under a CC-BY-NC-ND 4.0 International license. Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

Table 4. Hazard ratios for breast cancer, cervical cancer, ovary and fallopian tube cancer, anduterine cancer contrasting VB-affected pregnancy with comparator cohorts, Denmark, 1995-2018

		VB-affected vs VB- unaffected pregnancy ^{a,b}	VB-affected pregnancy vs termination ^{a,c}	VB-affected pregnancy vs miscarriage ^{a,c}
Outcome	Model		HR (95% CI)	
Breast cancer,	Crude	1.00 (0.92-1.10)	1.17 (1.06-1.29)	0.89 (0.81-0.99)
premenopausal	Adjusted	1.01 (0.92-1.11)	1.07 (0.97-1.18)	1.04 (0.93-1.17)
Conviced concer	Crude	0.95 (0.78-1.16)	0.88 (0.72-1.08)	1.09 (0.87-1.37)
Cervical cancer	Adjusted	0.95 (0.78-1.16)	0.82 (0.66-1.02)	1.01 (0.77-1.32)
Ovary and fallopian	Crude	1.28 (0.90-1.83)	1.21 (0.84-1.76)	0.96 (0.64-1.42)
tube cancer	Adjusted	1.20 (0.84-1.71)	0.96 (0.65-1.42)	0.88 (0.56-1.38)
Titoring gameen	Crude	0.85 (0.50-1.45)	1.01 (0.58-1.76)	0.70 (0.40-1.26)
Oterme cancer	Adjusted	0.83 (0.49-1.42)	0.96 (0.54-1.72)	0.77 (0.40-1.48)

^a Computed using all identifiable pregnancies of a woman

^b Adjusted for age, calendar year of pregnancy end, women's parity and number of previous identifiable pregnancies, socioeconomic factors (education, employment, and year-specific income level divided into quartiles based on all included pregnancies), smoking in pregnancy, reproductive history (pre-index date vaginal bleeding, termination, or miscarriages, placental complication in previous and current deliveries), history of chronic somatic conditions, any psychiatric condition, and use of NSAIDs and steroids for systemic use before the 12 weeks of gestation for VB-affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages ^c Analyses could not be adjusted for smoking in pregnancy since the data were unavailable for pregnancies ending in termination or miscarriage

CI, Confidence interval; HR, Hazard ratio; VB, vaginal bleeding

